A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis

Trial Profile

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms OCTAVE; OCTAVE Sustain
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2017 Results describing clinical efficacy endpoints assessed by local endoscopy readings and previously reported results assessed by central readings presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results of an integrated analysis assessing safety of Tofacitinib in NCT00787202, NCT01458574, NCT01458951, NCT01465763 and NCT01470612 (n=1240) presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results of pooled analysis assessing pregnancy outcomes data from four studies (OCTAVE Induction 1, OCTAVE Induction 2, Sustain and OCTAVE long-term) presented at the 25th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top